Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 14/20 | 0.79 |
| ▸ | CTSG | P08311 | 13/20 | 0.79 |
| ▸ | KLK14 | Q9P0G3 | 13/20 | 0.79 |
| ▸ | KLK5 | Q9Y337 | 13/20 | 0.79 |
| ▸ | CTRC | Q99895 | 4/20 | 0.79 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.76 |
| ▸ | C1R | P00736 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18353430 | 0.89 | KLK7 (1.00) | KLK7CTSGKLK14KLK5CTRC | |
| SCHEMBL18352896 | 0.86 | KLK7 (1.00) | KLK7CTSGKLK14KLK5CTRC | |
| SCHEMBL26480185 | 0.73 | KLK7 (0.72) | KLK7CTSGKLK14KLK5CTRC | |
| SCHEMBL26480187 | 0.73 | KLK7 (0.72) | KLK7CTSGKLK14KLK5CTRC | |
| SCHEMBL23159921 | 0.73 | KLK7 (0.74) | KLK7CTSGKLK14KLK5CTRC | |
| SCHEMBL29838660 | 0.73 | KLK7 (0.74) | KLK7CTSGKLK14KLK5CTRC | |
| SCHEMBL23159922 | 0.73 | KLK7 (0.70) | KLK7CTSGKLK14KLK5CTRC | |
| SCHEMBL23159923 | 0.73 | KLK7 (0.70) | KLK7CTSGKLK14KLK5CTRC | |
| SCHEMBL29838606 | 0.73 | KLK7 (0.70) | KLK7CTSGKLK14KLK5CTRC | |
| SCHEMBL18352858 | 0.72 | KLK7 (1.00) | KLK7CTSGKLK14KLK5CTRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3097085-B1 | BENZOXAZINONE DERIVATIVES FOR TREATMENT OF SKIN DISEASES | SIXERA PHARMA AB (SE) | 2020-07-29 | — | — | EP | disclosed |